Bio Logbook, a start-up specialising in precision medicine, has won the European COVID-X call for projects. The start-up will receive a grant of 150,000 euros to make its solution more easily available to doctors. Thanks to a decision support software coupled with a predictive algorithm, the tool detects the most at-risk patients with COVID-19. In September 2020, Bio Logbook was the winner ofthe EUREKA - International COVID-19 Challenge call for projects.

The European call for projects COVID-X

Supported by the European Commission, the call for projects "Data vs COVID-19 game on" was launched as part of the COVID-X research and innovation programme. About a hundred teams applied to participate and 16 solutions were rewarded. Each team is composed of a start-up and a medical institution.

The winners will be supported:

  • Financially: A grant of 100,000 euros for the start-up, 50,000 for the medical authority.
  • Through support: The winner will participate in a 10-month acceleration program on various topics such as regulatory mentoring, market, ethical and technical as well as access to a health data protection and analysis tool.
With these two grants, the goal is to optimize the organization of medical care thanks to technological tools and thus limit the overload of work for caregivers. The only French project chosen is that of the company Bio Logbook, in team with the CHU of Liège, for the detection of patients with the highest risk of developing COVID-19.

The creation of a tool adapted to COVID-19 thanks to a multiparametric algorithm

In 2015, the Nantes-based start-up was created to prevent diseases and contribute to better health. Their goal: to harness the power of big data to provide health professionals and researchers with monitoring, detection and prediction of phenomena based on biological data.

For example, Bio Logbook has developed a multi-parametric algorithm for patient complication risk, using the first laboratory test performed after the PCR test. According to the start-up, the extreme velocity of the disease implies a personalized management with a global and detailed overview of the patient's health status, as soon as he arrives at the hospital.

One of the goals of this tool is to guide practitioners to the most at-risk patients more quickly and thus save time on the organization of optimized care. For patients, this would represent a real opportunity for rapid care. This tool seems to be a real answer to counter the consequent time taken by doctors in order to carry out advanced analyses of all the biological measurements and clinical results of the infected patient.

A detection and predilection software

Bio Logbook has designed its software for the detection and prediction of early imbalances to the COVID-19 problem. The possibilities offered by the tool are the following:

The monitoring of the measured biological parameters :

  • Calculation of personalized early biological drifts
  • Identification of biological parameters predictive of complication risk
  • Graphical monitoring of the personalized evolution of the disease for each biological parameter, allowing the reading of variations within the reference thresholds.
Detection of additional biological parameters to be controlled:
  • Assistance in prescribing prognostic biological parameters to be monitored
  • Highlighting of biological parameters linked to the risk of complications
The prognosis of the risk of developing a severe form of COVID-19 for patients. A collaboration related to the academic validation of the first draft of this solution was signed in December 2018 with the University Hospital of Liege, in the framework of the European program Boost4Health. Thanks to this partnership, Bio Logbook was fortunate to have a dataset and expertise in biostatistics at its disposal. This cooperation continued during the COVID-19 pandemic in order to detect upstream the most at-risk patients and resulted in this solution focused on this disease.

Translated from La start-up française Bio Logbook, lauréate de l'appel à projets européen COVID-X